211 related articles for article (PubMed ID: 22025166)
1. Prostate brachytherapy and second primary cancer risk: a competitive risk analysis.
Hinnen KA; Schaapveld M; van Vulpen M; Battermann JJ; van der Poel H; van Oort IM; van Roermund JG; Monninkhof EM
J Clin Oncol; 2011 Dec; 29(34):4510-5. PubMed ID: 22025166
[TBL] [Abstract][Full Text] [Related]
2. Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study.
Nieder AM; Porter MP; Soloway MS
J Urol; 2008 Nov; 180(5):2005-9; discussion 2009-10. PubMed ID: 18801517
[TBL] [Abstract][Full Text] [Related]
3. Second malignancies after prostate brachytherapy: incidence of bladder and colorectal cancers in patients with 15 years of potential follow-up.
Liauw SL; Sylvester JE; Morris CG; Blasko JC; Grimm PD
Int J Radiat Oncol Biol Phys; 2006 Nov; 66(3):669-73. PubMed ID: 16887293
[TBL] [Abstract][Full Text] [Related]
4. Incidence of second malignancies in prostate cancer patients treated with low-dose-rate brachytherapy and radical prostatectomy.
Hamilton SN; Tyldesley S; Hamm J; Jiang WN; Keyes M; Pickles T; Lapointe V; Kahnamelli A; McKenzie M; Miller S; Morris WJ
Int J Radiat Oncol Biol Phys; 2014 Nov; 90(4):934-41. PubMed ID: 25240272
[TBL] [Abstract][Full Text] [Related]
5. Second primary cancer after radiotherapy for prostate cancer--a seer analysis of brachytherapy versus external beam radiotherapy.
Abdel-Wahab M; Reis IM; Hamilton K
Int J Radiat Oncol Biol Phys; 2008 Sep; 72(1):58-68. PubMed ID: 18374503
[TBL] [Abstract][Full Text] [Related]
6. Second primary cancers occurring after I-125 brachytherapy as monotherapy for early prostate cancer.
Musunuru H; Mason M; Murray L; Al-Qaisieh B; Bownes P; Smith J; Franks K; Carey B; Bottomley D; Henry AM
Clin Oncol (R Coll Radiol); 2014 Apr; 26(4):210-5. PubMed ID: 24507938
[TBL] [Abstract][Full Text] [Related]
7. Second primary cancer risk of radiation therapy after radical prostatectomy for prostate cancer: an analysis of SEER data.
Abdel-Wahab M; Reis IM; Wu J; Duncan R
Urology; 2009 Oct; 74(4):866-71. PubMed ID: 19628258
[TBL] [Abstract][Full Text] [Related]
8. The risk of second malignancies after
Fernandez Ots A; Browne L; Chin YS; Malouf D; Wong K; Bucci J
Brachytherapy; 2016; 15(6):752-759. PubMed ID: 27475483
[TBL] [Abstract][Full Text] [Related]
9. Risk of second malignancies in survivors of retinoblastoma: more than 40 years of follow-up.
Marees T; Moll AC; Imhof SM; de Boer MR; Ringens PJ; van Leeuwen FE
J Natl Cancer Inst; 2008 Dec; 100(24):1771-9. PubMed ID: 19066271
[TBL] [Abstract][Full Text] [Related]
10. Cancer incidence after localized therapy for prostate cancer.
Moon K; Stukenborg GJ; Keim J; Theodorescu D
Cancer; 2006 Sep; 107(5):991-8. PubMed ID: 16878323
[TBL] [Abstract][Full Text] [Related]
11. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.
Tsai HK; D'Amico AV; Sadetsky N; Chen MH; Carroll PR
J Natl Cancer Inst; 2007 Oct; 99(20):1516-24. PubMed ID: 17925537
[TBL] [Abstract][Full Text] [Related]
12. Second lymphomas and other malignant neoplasms in patients with mycosis fungoides and Sezary syndrome: evidence from population-based and clinical cohorts.
Huang KP; Weinstock MA; Clarke CA; McMillan A; Hoppe RT; Kim YH
Arch Dermatol; 2007 Jan; 143(1):45-50. PubMed ID: 17224541
[TBL] [Abstract][Full Text] [Related]
13. Risk of new primary nonbreast cancers after breast cancer treatment: a Dutch population-based study.
Schaapveld M; Visser O; Louwman MJ; de Vries EG; Willemse PH; Otter R; van der Graaf WT; Coebergh JW; van Leeuwen FE
J Clin Oncol; 2008 Mar; 26(8):1239-46. PubMed ID: 18323547
[TBL] [Abstract][Full Text] [Related]
14. Association of colorectal cancer and prostate cancer and impact of radiation therapy.
Huo D; Hetzel JT; Roy H; Rubin DT
Cancer Epidemiol Biomarkers Prev; 2009 Jul; 18(7):1979-85. PubMed ID: 19531678
[TBL] [Abstract][Full Text] [Related]
15. Increasing age and treatment modality are predictors for subsequent diagnosis of bladder cancer following prostate cancer diagnosis.
Singh AK; Mashtare TL; McCloskey SA; Seixas-Mikelus SA; Kim HL; May KS
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1086-94. PubMed ID: 20350797
[TBL] [Abstract][Full Text] [Related]
16. Risk of subsequent primary cancer among prostate cancer patients in Bavaria, Germany.
Braisch U; Meyer M; Radespiel-Tröger M
Eur J Cancer Prev; 2012 Nov; 21(6):552-9. PubMed ID: 22433633
[TBL] [Abstract][Full Text] [Related]
17. Incidence of urethral stricture after primary treatment for prostate cancer: data From CaPSURE.
Elliott SP; Meng MV; Elkin EP; McAninch JW; Duchane J; Carroll PR;
J Urol; 2007 Aug; 178(2):529-34; discussion 534. PubMed ID: 17570425
[TBL] [Abstract][Full Text] [Related]
18. Radiation therapy for prostate cancer increases the risk of subsequent rectal cancer.
Margel D; Baniel J; Wasserberg N; Bar-Chana M; Yossepowitch O
Ann Surg; 2011 Dec; 254(6):947-50. PubMed ID: 22107741
[TBL] [Abstract][Full Text] [Related]
19. Risk of a second malignant neoplasm among 5-year survivors of cancer in childhood and adolescence in British Columbia, Canada.
MacArthur AC; Spinelli JJ; Rogers PC; Goddard KJ; Phillips N; McBride ML
Pediatr Blood Cancer; 2007 Apr; 48(4):453-9. PubMed ID: 16767718
[TBL] [Abstract][Full Text] [Related]
20. Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer.
van den Belt-Dusebout AW; de Wit R; Gietema JA; Horenblas S; Louwman MW; Ribot JG; Hoekstra HJ; Ouwens GM; Aleman BM; van Leeuwen FE
J Clin Oncol; 2007 Oct; 25(28):4370-8. PubMed ID: 17906202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]